308 related articles for article (PubMed ID: 34480795)
1. Tramadol-Related Deaths: Genetic Analysis in Relation to Metabolic Ratios.
Aly SM; Tartar O; Sabaouni N; Hennart B; Gaulier JM; Allorge D
J Anal Toxicol; 2022 Aug; 46(7):791-796. PubMed ID: 34480795
[TBL] [Abstract][Full Text] [Related]
2. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
3. Physiologically based pharmacokinetic modeling of tramadol to inform dose adjustment and drug-drug interactions according to CYP2D6 phenotypes.
Xu M; Zheng L; Zeng J; Xu W; Jiang X; Wang L
Pharmacotherapy; 2021 Mar; 41(3):277-290. PubMed ID: 33316842
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype.
García-Quetglas E; Azanza JR; Sádaba B; Muñoz MJ; Gil I; Campanero MA
Pharmacol Res; 2007 Feb; 55(2):122-30. PubMed ID: 17175164
[TBL] [Abstract][Full Text] [Related]
5. Metabolic ratios and SNPs implicated in tramadol-related deaths.
Aly SM; Hakim F; Richeval C; Hennart B; Gaulier JM; Allorge D
Int J Legal Med; 2023 Sep; 137(5):1431-1437. PubMed ID: 37460702
[TBL] [Abstract][Full Text] [Related]
6. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients.
Halling J; Weihe P; Brosen K
Ther Drug Monit; 2008 Jun; 30(3):271-5. PubMed ID: 18520597
[TBL] [Abstract][Full Text] [Related]
7. Association between aripiprazole pharmacokinetics and CYP2D6 phenotypes: A systematic review and meta-analysis.
Zhang X; Xiang Q; Zhao X; Ma L; Cui Y
J Clin Pharm Ther; 2019 Apr; 44(2):163-173. PubMed ID: 30565279
[TBL] [Abstract][Full Text] [Related]
8. Impact of CYP2D6 and CYP2B6 phenotypes on the response to tramadol in patients with acute post-surgical pain.
Casajús A; Zubiaur P; Alday E; Soria-Chacartegui P; Saiz-Rodríguez M; Gutierrez L; Aragonés C; Campodónico D; Gómez-Fernández A; Navares-Gómez M; Villapalos-García G; Mejía-Abril G; Ochoa D; Abad-Santos F
Clin Transl Sci; 2024 Jan; 17(1):e13698. PubMed ID: 38140786
[TBL] [Abstract][Full Text] [Related]
9. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
[TBL] [Abstract][Full Text] [Related]
10. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Zhou SF
Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
[TBL] [Abstract][Full Text] [Related]
11. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers.
Pedersen RS; Damkier P; Brøsen K
Eur J Clin Pharmacol; 2006 Jul; 62(7):513-21. PubMed ID: 16763825
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.
Zanger UM; Fischer J; Raimundo S; Stüven T; Evert BO; Schwab M; Eichelbaum M
Pharmacogenetics; 2001 Oct; 11(7):573-85. PubMed ID: 11668217
[TBL] [Abstract][Full Text] [Related]
13. Sequencing CYP2D6 for the detection of poor-metabolizers in post-mortem blood samples with tramadol.
Fonseca S; Amorim A; Costa HA; Franco J; Porto MJ; Santos JC; Dias M
Forensic Sci Int; 2016 Aug; 265():153-9. PubMed ID: 26926096
[TBL] [Abstract][Full Text] [Related]
14. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes.
Stamer UM; Musshoff F; Kobilay M; Madea B; Hoeft A; Stuber F
Clin Pharmacol Ther; 2007 Jul; 82(1):41-7. PubMed ID: 17361124
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
Løvlie R; Daly AK; Matre GE; Molven A; Steen VM
Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030
[TBL] [Abstract][Full Text] [Related]
16. Gender Dependency in Streoselective Pharmacokinetics of Tramadol and Its Phase I Metabolites in Relation to CYP2D6 Phenotype in Iranian Population.
Hosseinzadeh Ardakani Y; Lavasani H; Rouini MR
Iran J Pharm Res; 2018; 17(2):767-782. PubMed ID: 29881433
[TBL] [Abstract][Full Text] [Related]
17. The effects of tramadol on static and dynamic pupillometry in healthy subjects--the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status.
Fliegert F; Kurth B; Göhler K
Eur J Clin Pharmacol; 2005 Jun; 61(4):257-66. PubMed ID: 15906019
[TBL] [Abstract][Full Text] [Related]
18. Correlation of genotype, phenotype, and mRNA expression of CYP2D6 and CYP2C19 in peripheral blood leukocytes (PBLs).
Kuhlmann JB; Wensing G; Kuhlmann J
Int J Clin Pharmacol Ther; 2014 Feb; 52(2):143-50. PubMed ID: 24361088
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships.
Chou WH; Yan FX; Robbins-Weilert DK; Ryder TB; Liu WW; Perbost C; Fairchild M; de Leon J; Koch WH; Wedlund PJ
Clin Chem; 2003 Apr; 49(4):542-51. PubMed ID: 12651805
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
